Avantor(US:AVTR)2022-02-04 14:09Financial Performance - Fourth quarter organic revenue grew by 2.5%, driven by Biopharma and ATAM, with core growth at approximately 4.6% and COVID-19 headwinds of approximately 2.1%[8] - Fourth quarter adjusted EBITDA increased by 15.6%, reflecting mix, inflation management, and productivity, with over 150 bps margin expansion, including approximately 90 bps from M&A[8] - Fourth quarter adjusted EPS grew by 21.4%, driven by execution and benefits from interest and tax initiatives[8] - Full-year 2021 organic revenue growth reached 11.3%, exceeding initial guidance of 4-7%[9] - Full-year 2021 adjusted EPS growth was 57.7%, surpassing initial guidance of approximately 30%[9] - Full-year 2021 free cash flow was $920 million, exceeding initial guidance of approximately $800 million[9] Strategic Initiatives and Outlook - The company closed the acquisition of Masterflex, expanding its single-use offering for bioproduction workflows[7] - The company launched LC/MS consumables from Agilent Technologies to enhance workflow solutions[7] - Initial 2022 guidance includes organic revenue growth of 4-6% and reported growth of 7-9%[23] - The company anticipates adjusted EBITDA margin expansion of over 125 bps in 2022, approaching 21%[23] - The company projects 2022 adjusted EPS to be in the range of $1.45-$1.53, representing a reported growth of 10-16%[23]